Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multimodality Cardiovascular Imaging Reveals Late Recurrence of Cardiac Neoplasm.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026

Same author

Deep Computational Anatomy via Latent-Aligned Multiview Normalizing Flows.

bioRxiv : the preprint server for biology·2026

Same author

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease.

Alzheimer's research & therapy·2026

Same author

Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026

Same author

Sigma-2 receptor modulators alter low-density lipoprotein receptor-mediated lipid uptake in retinal pigment epithelial cells.

Experimental eye research·2026

Same author

Case 1-2026: A 50-Year-Old Woman with Fever and Abdominal Pain.

The New England journal of medicine·2026

Search research articles

Related Experiment Video

Updated: Jun 19, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins.

Yun Bian¹, Maoyun Sun, Marcy Silver

¹Cardiovascular Research, Caritas St. Elizabeth's Medical Center, 736 Cambridge St. CBR3, Boston, MA 02135, USA.

American Journal of Physiology. Heart and Circulatory Physiology

|October 6, 2009

Summary

Neuregulin-1 (NRG1) protects against doxorubicin (Dox)-induced heart failure by maintaining cardiac troponin levels. This protection involves the NRG1-erbB2 pathway, which increases protein synthesis and reduces degradation, thereby preserving heart function.

Related Experiment Videos

Last Updated: Jun 19, 2026

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

Area of Science:

Cardiology
Molecular Biology
Pharmacology

Background:

Doxorubicin (Dox) is a potent chemotherapy agent with known cardiotoxicity.
Neuregulin-1 (NRG1) shows potential for treating Dox-induced heart failure.
NRG1 activates the erbB2 receptor, which is overexpressed in some cancers, necessitating a clear understanding of its cardioprotective mechanisms.

Purpose of the Study:

To elucidate the molecular mechanisms by which NRG1, via erbB2 signaling, protects the heart against Dox-induced cardiotoxicity.
To investigate the effects of NRG1 on cardiac troponin levels and related signaling pathways in the context of Dox treatment.

Main Methods:

NRG1 was administered to Dox-treated mice and isolated neonatal rat ventricular myocytes (NRVM).
Cardiac function and survival were assessed in mice.
Western blot analysis was used to measure cardiac troponins (cTnI, cTnT, cTnC) and phosphorylated Akt.
Caspase activation and protein degradation pathways (ubiquitinylation, proteasome) were analyzed in NRVM.

Main Results:

NRG1 significantly improved survival and cardiac function in Dox-treated mice.
NRG1 preserved cardiac troponin levels (cTnI, cTnT, cTnC) and maintained Akt phosphorylation in Dox-treated hearts.
NRG1 reduced Dox-induced decreases in troponin mRNA and protein in NRVM.
Inhibition of the erbB2-PI3K-Akt-mTOR pathway blocked NRG1's protective effects.
NRG1 inhibited Dox-induced caspase activation and proteasome degradation of troponins.

Conclusions:

NRG1 attenuates Dox-induced cardiac troponin reduction by enhancing transcription/translation and inhibiting caspase-mediated degradation and proteasome degradation.
The cardioprotective effects of NRG1 are mediated through the erbB2-PI3K-Akt pathway.
NRG1 represents a promising therapeutic strategy to mitigate Dox-induced cardiotoxicity.